Generic medicines

FDA aims to speed up approvals of generic drugs

New guidance highlights common deficiencies in generic drug applications to help applicants gain approval more quickly.

Generic medicines ss 18

Source: Shutterstock.com

New guidance published by the FDA highlights common deficiencies in generic drug applications to help applicants gain approval more quickly

The US Food and Drug Administration (FDA) has published guidance aimed at speeding up approvals of generic drugs, helping manufacturers reduce the number of reviews needed to gain approval.

The guidance, ‘Good ANDA [Abbreviated New Drug Application] Submission Practices’, highlights common and recurring deficiencies the FDA says it sees in generic drug applications that often lead to their applications being delayed after undergoing multiple reviews.

It takes on average around four review cycles for an ANDA to reach approval, often because an application is missing necessary information.

The FDA is also publishing companion literature ‘’, which formalises the outline of more streamlined ANDA assessment practices for FDA staff.

The review process will now include templates aimed at making the process more efficient and complete.

More support offered

The MAPP sets out that when the FDA has found an ANDA cannot be approved in its current form, application reviewers should provide more detail to the applicants to explain the issues with the applications.

They can also outline details on what information should be provided and give more detail on what additional information a further application would need to support the approval of an application.

In a , FDA commissioner Scott Gottlieb said: “There are many times when the FDA must ask applicants for additional information to determine that the requirements for approval have been met, even if an application meets the threshold requirements for filing. These multiple cycles of review are costly and inefficient.”

The moves have been undertaken as part of the FDA’s Drug Competition Action Plan, which in addition to improving the generic review process, aims to reduce gaming by branded companies and resolve scientific and regulatory obstacles that can make it difficult to win approval of generic versions of some drugs.

Citation: The Salvadore DOI: 10.1211/PJ.2018.20204193

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Physicochemical Principles of Pharmacy

    This established textbook covers every aspect of drug properties from the design of dosage forms to their delivery by all routes to sites of action in the body.

    £48.00
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00
  • FASTtrack: Pharmacology

    FASTtrack: Pharmacology is a study guide providing an account of drug action, as well as dealing with molecular pharmacology at a more advanced level.

    £25.00
  • Introduction to Statistics in Pharmaceutical Clinical Trials

    An innovative book which presents statistics in the context of clinical trials conducted during pharmaceutical drug development.

    £38.00
  • Basic Pharmacokinetics

    A clear and concise basic pharmacokinetics textbook. Shows how to apply the principles to achieve successful drug therapy.

    £54.00

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete

Supplementary images

  • Generic medicines ss 18

Jobs you might like

  • London Bridge/Work from Home

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.

левитра купить львов

сиалис львов

дженерик сиалис